Inequity in smoking cessation clinical trials testing pharmacotherapies: exclusion of smokers with mental health disorders

Conclusion Smokers with MHDs are not sufficiently represented in RCTs examining the safety and effectiveness of smoking cessation medications. Greater access to clinical trial participation needs to be facilitated for this group to better address access to appropriate pharmacotherapeutic interventions in this vulnerable population.
Source: Tobacco Control - Category: Respiratory Medicine Authors: Tags: Open access Review Source Type: research